<unk>  is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).<unk>  may be used as monotherapy or in combination with methotrexate.
Upadacitinib
Abrocitinib
Selpercatinib
Baricitinib
Erdafitinib
Oclacitinib
Dacomitinib
Axitinib